{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0014","statisticalMethod":"Chi-squared","testedNonInferiority":false},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"116"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"Mucosal healing is determined from the endoscopy sub-score of the Mayo score. Mucosal healing is defined as an endoscopy sub-score of 0 or 1. Higher score indicates higher severity of disease. Endoscopy sub-score ranges from 0 (normal or inactive disease) to 3 (severe disease; spontaneous bleeding and ulceration).","groups":[{"description":"Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.","id":"OG000","title":"Placebo"},{"description":"Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.","id":"OG001","title":"Golimumab 200 mg -> 100 mg"},{"description":"Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.","id":"OG002","title":"Golimumab 400 mg -> 200 mg"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis population included all the participants who were randomly assigned to the study after the dose selection.","reportingStatus":"POSTED","timeFrame":"Week 6","title":"Number of Participants With Mucosal Healing at Week 6","type":"SECONDARY","unitOfMeasure":"Participants"}